Table 1 Detailed indications for rituximab treatment

Rheumatoid arthritis

105 (51.7)

 Including ACPA positive

77/105 (73.3)

 Including RF positive

79/105 (75.2)

 Seronegative rheumatoid arthritis (RF and ACPA negative)

17/105 (16.2)

Connective tissue diseases

 Systemic lupus erythematosus

15 (7.4)

 Overlap syndrome (connective tissue disease)

15 (7.4)

 Sjögren syndrome

10 (4.9)

 Undifferentiated connective tissue disease

8 (3.9)

 Dermato-/polymyositis

7 (3.5)

 Mixed connective tissue disease (MCTD)

3 (1.5)

 Systemic sclerosis

2 (1.0)

Vasculitis

 Microscopic polyangiitis (MPA)

6 (3.0)

 Granulomatosis with polyangiitis (GPA)

5 (2.5)

 Vasculitis (other)

5 (2.5)

 Hepatitis C-associated cryoglobulinemic vasculitis

4 (2.0)

Other

 Ankylosing spondylarthritis

3 (1.5)

 Psoriatic arthritis^a

1 (0.5)

 Behçet disease

1 (0.5)

 Sarcoidosis

1 (0.5)

 Glomerulonephritis

1 (0.5)

 Immune thrombocytopenic purpura

1 (0.5)

 Autoimmune haemolytic anaemia

1 (0.5)

 Antiphospholipid antibody syndrome

1 (0.5)

 Myasthenia gravis

1 (0.5)

 Interstitial lung disease

1 (0.5)

 Scleritis

1 (0.5)

 Autoimmune hepatitis

1 (0.5)

 Primary biliary cholangitis-related arthritis

1 (0.5)

 Calcium pyrophosphate dihydrate crystal-related arthritis^a

1 (0.5)

 Hereditary myopathy^a

1 (0.5)

 Motor neurone disease^a

1 (0.5)